HSP90 Inhibitors of Protein-Protein Interaction HSP90 Chaperone Complexes and Therapeutic Uses Thereof

(canceled)

(canceled)

A method for treating a disease condition in a subject, comprising:

• providing a Hps90 inhibitor that disrupts protein-protein interaction in Hsp90 superchaperone complex without blocking ATP binding;
• and administering the Hsp90 inhibitor to the mammal in an amount sufficient to treat the disease condition.

(canceled)

(canceled)

(canceled)

A method for inhibiting Hsp90 in a subject in need thereof, comprising disrupting Hsp90-Cdc37 complex in a cell without affecting the ATP/ADP binding of Hsp90 in the cell.

A method for disrupting Hsp90-Cdc37 in a pancreatic cancer cell, comprising degrading Hsp90 client proteins by administering an effective amount of celastrol.

(canceled)

A Hsp90 inhibitor, comprising a composition that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding, wherein a cyclohexa dienone moiety of the Hsp90 inhibitor is capable of binding to a polar groove of Hsp90 defined by several residues in the lid segment (residues #94 to #125) and the mouth of the nucleotide-binding pocket.

(canceled)

A method of identifying an anti-pancreatic cancer agent, comprising

• providing a test agent to a cell and measuring the level of a Hsp90 inhibitor that disrupts protein-protein interaction in a Hsp90 superchaperone complex without blocking ATP binding associated with decreased expression levels in pancreatic cancer cells,
• wherein an increase or a decrease in the level of the Hsp90 inhibitor in the cell, relative to a control cell, is indicative of the test agent being an anti-pancreatic cancer agent.

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)